Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Cerilliant
McKesson
Dow
Cantor Fitzgerald
Express Scripts
Cipla
Covington
UBS
Johnson and Johnson

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022504

« Back to Dashboard
NDA 022504 describes AXIRON, which is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from three suppliers. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the AXIRON profile page.

The generic ingredient in AXIRON is testosterone. There are sixty-one drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

Summary for NDA: 022504

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:11
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details

Pharmacology for NDA: 022504

Ingredient-typeAndrostanes
Mechanism of ActionAndrogen Receptor Agonists

Suppliers and Packaging for NDA: 022504

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL 022504 NDA Eli Lilly and Company 0002-1975 0002-1975-61 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0002-1975-61) > 90 mL in 1 BOTTLE, WITH APPLICATOR
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL 022504 NDA Eli Lilly and Company 0002-1975 0002-1975-90 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0002-1975-90) > 90 mL in 1 BOTTLE, WITH APPLICATOR

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION, METERED;TRANSDERMALStrength30MG/1.5ML ACTUATION
Approval Date:Nov 23, 2010TE:ATRLD:Yes
Patent:► SubscribePatent Expiration:Feb 26, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
Patent:► SubscribePatent Expiration:Sep 27, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
Patent:► SubscribePatent Expiration:Jun 2, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF

Expired Orange Book Patents for NDA: 022504

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Fuji
Covington
Dow
Merck
Federal Trade Commission
Accenture
Julphar
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot